KEYTRUDA + Paclitaxel +/- Bevacizumab Significantly Improved OS vs Paclitaxel +/- Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer March 3, 2026
WELIREG + LENVIMA Reduced the Risk of Disease Progression or Death by 30% vs Cabozantinib in Certain Previously Treated Patients With Advanced RCC March 3, 2026
Adjuvant KEYTRUDA + WELIREG Reduced the Risk of Disease Recurrence or Death by 28% vs KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage RCC March 3, 2026
Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ NSCLC in New Results from the eNRGy Trial February 25, 2026
First Interim Analysis in the Global Phase 3 FIERCE-HN Study of ficlatuzumab Completed February 25, 2026
Encouraging Patient Survival Observations Reported in Ovarian Cancer Lira-cel CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation February 17, 2026
Ph 3 LIBRETTO-432 trial of Retevmo (selpercatinib) met primary endpoint of EFS in patients with early-stage (II-IIIA) RET fusion-positive NSCLC February 17, 2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall DCR in Melanoma Announced February 9, 2026
Positive Year-End Interim Clinical Progress from Ph 2 Study of Ampligen – Imfinzi Combo in Pancreatic Cancer Reported February 9, 2026
Results announced from Ph 3 study of Anbenitamab (KN026) in HER2+ve gastric or gastroesophageal junction cancer (GC/GEJ) February 1, 2026
Positive Ph 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer Reported February 1, 2026
Positive Results from Ph 1b/2 PESCO Trial of MVP-S, Keytruda and Cyclophosphamide in Recurrent Epithelial Ovarian Cancer (EOC) Reported February 1, 2026
Preliminary Results from Ph 2 Study of PDS01ADC in 3L Metastatic CRPC by the NCI to be presented February 1, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to Evorpacept in Combination with Ziihera in HER2+ve Breast Cancer February 1, 2026
Updated Interim Data from Ph 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients to be Presented January 25, 2026
5-Year Data for Intismeran Autogene + KEYTRUDA combo Demonstrated Sustained RFS Improvement in High-Risk Stage III/IV Melanoma Following Complete Resection January 25, 2026
Positive Results from Ph 1B/2 PESCO Trial of MVP-S with Keytruda and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) Announced January 25, 2026
NEJM Publishes Ph 3 ASCENT-04/KEYNOTE-D19 Results of Trodelvy + Keytruda in 1L PD-L1+ Metastatic TNBC January 25, 2026
OS Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer January 25, 2026
Positive interim results announced from PK cohort of CLEER-001 trial of HT-001 in cancer patients receiving EGFR inhibitor therapy January 25, 2026
Median OS Not Yet Reached and Lymphopenia Reversed in Recurrent GBM Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy January 25, 2026
Ph 3 KANDLELIT-007 Trial of Calderasib + KEYTRUDA QLEX™ Merck Initiated in Certain Patients With Advanced NSCLC January 18, 2026
